Baird Initiates Coverage On Larimar Therapeutics with Outperform Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
Baird has initiated coverage on Larimar Therapeutics with an Outperform rating and set a price target of $16.
September 04, 2024 | 9:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird has initiated coverage on Larimar Therapeutics with an Outperform rating and a price target of $16, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $16 by Baird suggests a positive sentiment towards Larimar Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100